Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) announced updates to its oncology innovation roadmap at the 43rd Annual J.P. Morgan Healthcare Conference. The company introduced three key developments:
1. A new version of Signatera leveraging whole genome sequencing (WGS), now available for research and clinical use, detecting down to low single-digit parts per million.
2. A novel tissue-free molecular residual disease (MRD) capability, with first launch expected in mid-2025 for colorectal cancer (CRC), utilizing methylation-based technologies.
3. Preliminary data for their Early Cancer Detection (ECD) assay, showing 92% detection of stage 1 CRC and 95% detection overall, with 91% specificity. The company plans to present additional data from the PROCEED-CRC cohort later this year, followed by an FDA-grade validation study if results are positive.
Natera (NTRA) has released preliminary unaudited results for Q4 and full-year 2024, showing significant growth across key metrics. The company expects Q4 2024 revenues of approximately $472 million, up 52% from Q4 2023, and full-year 2024 revenues of approximately $1.7 billion, representing a 56% increase from 2023.
Test volumes showed strong growth, with 792,800 tests processed in Q4 2024 (26.5% increase) and 3,064,600 tests for full-year 2024 (22.8% increase). Notably, oncology testing saw substantial growth, with 150,800 oncology tests in Q4 2024, marking a 54.7% increase. The company achieved positive cash inflows of $45.8 million in Q4 2024 and $86.3 million for full-year 2024, compared to previous year's cash outflows.
Natera (NASDAQ: NTRA), a leading cell-free DNA testing company, has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation and conduct a Q&A session with investors on Wednesday, January 15, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
Interested parties can access a live webcast of the event through the investor relations section of Natera's website at investor.natera.com. A recording of the presentation will be made available shortly after the conference concludes.
Natera (NASDAQ: NTRA) has expanded its patent infringement lawsuit against NeoGenomics by adding U.S. Patent No. 11,319,596 to the case. The District Court for the Middle District of North Carolina granted Natera's request on December 10, 2024. The amended complaint now includes both the '596 and previously asserted '454 patents, claiming infringement by NeoGenomics' modified RaDaR® test for molecular residual disease. This legal action follows earlier court decisions in December 2023 and September 2024 that resulted in preliminary and permanent injunctions against NeoGenomics' previous version of the RaDaR® test. Natera is pursuing full remedies, including injunctive relief, against NeoGenomics' current RaDaR® test offering.
Natera has announced the enrollment of the first patients in the SAGITTARIUS clinical trial, a phase III study aimed at using Signatera to guide personalized adjuvant treatment strategies for colon cancer. Sponsored by the AIRC Institute of Molecular Oncology and funded by the European Union Horizon Europe Programme, the study plans to enroll 700-900 patients across more than 20 sites. The trial will compare genotype-guided therapy versus standard chemotherapy for Signatera-positive patients and explore the use of immunotherapy and targeted agents earlier in the disease course. For Signatera-negative patients, the trial will assess treatments chosen by physicians, with options for observation or single-agent capecitabine. SAGITTARIUS involves collaborations with 9 partners in 5 European countries and a network of 26 clinical centers in Italy, Spain, and Germany. The trial aims to personalize treatment approaches and potentially reduce chemotherapy for certain patients.
Natera (NASDAQ: NTRA) and MyOme have launched an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. This new tool is offered with Natera's Empower hereditary cancer test and reports 5-year and lifetime breast cancer risk. iPRS provides further risk assessment for individuals who test negative for hereditary cancer mutations, enhancing predictions beyond the traditional Tyrer-Cuzick (T-C) model. A validation study of over 130,000 women, published in JCO Precision Oncology, showed that MyOme's cross-ancestry iPRS significantly improved breast cancer risk prediction, reclassifying up to 8% of women's T-C lifetime risk. This score integrates over 1 million single nucleotide polymorphisms (SNPs) from whole genome sequencing with T-C clinical inputs, offering a comprehensive risk assessment based on genetic ancestry. iPRS aims to identify higher-risk individuals, enabling proactive screening and early treatment, important for improving breast cancer outcomes. iPRS is available to women aged 18-85 with no personal history of breast cancer and no mutations in breast cancer-related genes.
Natera (NASDAQ: NTRA) announced the publication of its clinical validation study on the Fetal RhD noninvasive prenatal test (NIPT) in Obstetrics & Gynecology. This study, the largest of its kind in the U.S., demonstrated high performance metrics with 100% sensitivity and 99.3% specificity. The study involved 655 RhD-negative pregnant patients, confirming fetal RhD status via newborn serology. Key results included 356/356 fetuses correctly identified as RhD positive and 295/297 as RhD negative. The test also showed a positive predictive value of 99.4% and a negative predictive value of >99.9%. The study emphasized the test's potential to assist in the prevention and management of RhD alloimmunization, especially amid RhIg shortages. The NGS-based test can identify RHD pseudogene and hybrid variants common in non-European ancestries. Experts highlight the test's potential to transform care for RhD-negative pregnant patients, aligning with ACOG's guidance on cfDNA screening for fetal RhD testing.
Natera announced that its Prospera Lung test has received Medicare coverage from CMS's MolDX Program for single lung transplant (SLT) recipients in surveillance settings. SLT patients represent ~20% of U.S. lung transplants and face higher risks of rejection and biopsy complications. The test's performance was validated in the SLAM study, showing an AUC-ROC of 0.85 in distinguishing rejection, infection, and CLAD from stable patients, with 77.8% sensitivity, 84.6% specificity, and 96.8% NPV. Prospera Lung is now used by over half of U.S. lung transplant centers.
Natera (NASDAQ: NTRA) announced its upcoming presentation of new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), December 10-13. The company will present six abstracts, including significant findings from the ZEST clinical trial, which showed improved disease-free survival with niraparib treatment in ctDNA-positive breast cancer patients (11.4 months vs 5.4 months for placebo).
Key highlights include a clinical genomics study revealing 44% of Signatera-positive patients had targetable genomic alterations, with 34.5% showing PIK3CA mutations. Additionally, four abstracts will present patient-reported outcomes indicating that ctDNA testing provides valuable treatment planning information without increasing patient anxiety.
A federal court jury unanimously ruled in favor of Guardant Health in its lawsuit against Natera for false advertising and unfair competition. The jury awarded $292.5 million to Guardant Health, including $175.5 million in punitive damages, making it one of the largest false advertising verdicts in history. The case, filed in May 2021, centered on Natera's deliberate campaign to mislead cancer clinicians about Guardant Reveal™, a tissue-free minimal residual disease test for early-stage colorectal cancer. The jury rejected all of Natera's counterclaims.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
